Kelowna, British Columbia — November 4, 2025 — Leads & Copy — Rize Oncology Inc. (OTC: RZONF) completed a non-brokered private placement on October 30, 2025, raising C$500,000. The placement involved issuing 5,000,000 units at C$0.10 each. Each unit includes a common share and a warrant, with each warrant allowing the holder to buy another common share at C$0.30 for 12 months. These securities have a four-month hold period as per securities laws.
Additionally, William Garner, M.D., resigned from the board on October 31, 2025. The company thanked Dr. Garner for his service.
The private placement was a “related party transaction” under Multilateral Instrument 61-101 due to participation by insiders William Garner, M.D., and Andre Pereira Fraga Figueiredo. The company relied on exemptions within MI 61-101, as the transaction’s value did not exceed 25% of the company’s market capitalization. The board approved the placement, with conflicted directors abstaining. A material change report wasn’t filed 21 days prior because insider participation was confirmed shortly before completion.
Rize Oncology Inc. focuses on developing STS-201, a small-molecule drug for treating soft tissue sarcoma and other cancers.
Contact: P. Gage Jull, 416-562-7525, gagejull1@gmail.com
Source: Rize Oncology Inc.
